Related references
Note: Only part of the references are listed.Broadening horizons with 225Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to 177Lu-DOTATATE PRRT: first clinical experience on the efficacy and safety
Sanjana Ballal et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2020)
Peptide Receptor Radionuclide Therapy Using Ac-225-DOTATOC Achieves Partial Remission in a Patient With Progressive Neuroendocrine Liver Metastases After Repeated beta-Emitter Peptide Receptor Radionuclide Therapy
Jingjing Zhang et al.
CLINICAL NUCLEAR MEDICINE (2020)
Supply and Clinical Application of Actinium-225 and Bismuth-213
Alfred Morgenstern et al.
SEMINARS IN NUCLEAR MEDICINE (2020)
Targeted alpha therapy with bismuth-213 and actinium-225: Meeting future demand
Frank Bruchertseifer et al.
JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS (2019)
Targeted Alpha Particle Therapy for Neuroendocrine Tumours: The Next Generation of Peptide Receptor Radionuclide Therapy
Shaunak Navalkissoor et al.
NEUROENDOCRINOLOGY (2019)
Neuroendocrine tumors of the thymus and mediastinum
Hanibal Bohnenberger et al.
JOURNAL OF THORACIC DISEASE (2017)
Thymic Neuroendocrine Tumors A SEER Database Analysis of 160 Patients
Puja Gaur et al.
ANNALS OF SURGERY (2010)
Share Paper
